NeuroSense Therapeutics, Inc. (NASDAQ: NRSN) is a clinical-stage biotechnology company, which is focused on the research and development of therapies for the treatment of neurodegenerative diseases. Shares of the biotech company are surging 55% through early trading on Monday, June 27, 2022. Over the past three months, NeuroSense Therapeutics has seen average daily volume of 470,030 shares. However, volume of 59.18 million shares or dollar volume of around $165.11 million, has already exchanged hands through early trading.
Shares of NeuroSense Therapeutics are rallying after the company disclosed clinical results from its Stage III biomarker study to test PrimeC’s treatment ability for amyotrophic lateral sclerosis (ALS). The study was conducted in collaboration with Massachusetts General Hospital, as PrimeC currently undergoes Phase IIb PARADIGM study after a successful Phase IIa study, which met all primary endpoints.
Early results from the Stage III biomarker study showed a statistically significant decline in biomarkers among patients that were treated with PrimeC during the Phase IIa study, compared to patients receiving standard of care. This preliminary data validates NeuroSense’s clinical strategy.
Stage I biomarker study seeks to serve as a baseline phenomenon for patients suffering from ALS. The Stage II study determines the therapeutic effect of the drug candidate, PrimeC. Stage III is a natural history study analyzing blood samples of patients who are living with ALS and receiving the standard of care.
“NeuroSense remains at the forefront of biomarker research with the inclusion of a comprehensive portfolio of biomarkers in our Phase IIb study. This is essential in exploring mechanistic associations in ALS,” stated Dr. Shiran Zimri, Head of Scientific Programs at NeuroSense. “The use of neuronal derived exosomes (NDE), a cutting-edge technology, allows one to observe key alterations in biomarkers found in the central nervous system. We look forward to sharing more detailed results at the upcoming World Orphan Drug Congress in Boston, Massachusetts on July 11-13th.”
Disclosure: No position. Spotlight Growth has no relationships with any of the companies mentioned in this article and did not receive payment in any form for its creation. This is an opinion article and is not meant to be financial advise. We are not broker-dealers or investment professionals. Please conduct your own due diligence. For more information on our disclosures, please visit: https://spotlightgrowth.com/disclosures/